BALTIMORE, Aug 26, 2010 (GlobeNewswire via COMTEX) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has published a research update on Radient Pharmaceuticals Corporation /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 0.44, -0.02, -4.26%) , a leading in-vitro diagnostics test kits provider, with a focus on the oncology/cancer segment.
Radient has won FDA approval for its lead product as a post-surgery colorectal cancer monitoring test and is the only approved product in key markets abroad as a general cancer screen. As part of its diagnostics focus, Radient is in the midst of monetizing non-core assets and business lines through divestitures and out-licensing.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"Radient is well-positioned to lead the global charge in a $1 billion market for a general cancer screen test kit, which could potentially save lives and substantial sums of money otherwise used for treatment. We view Radient as a stock that offers great value and potential for its existing operations, hidden but soon-to-be monetized value in its non-core assets, and home run potential with its cancer screen platform. A steady stream of news and events in the coming months should serve as catalysts for the stock," Goldman commented.
